Skip to Content

Chugai Pharmaceutical Co Ltd CHGCF

Morningstar Rating
$29.75 −2.68 (8.26%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CHGCF is trading at a 238% premium.
Price
$29.67
Fair Value
$69.78
Uncertainty
Medium
1-Star Price
$98.73
5-Star Price
$41.46
Economic Moat
Xkfpw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CHGCF is a good fit for your portfolio.

Trading Information

Previous Close Price
$32.43
Day Range
$29.7529.75
52-Week Range
$26.6143.72
Bid/Ask
$29.65 / $32.28
Market Cap
$48.95 Bil
Volume/Avg
2,614 / 2,409

Key Statistics

Price/Earnings (Normalized)
22.60
Price/Sales
6.83
Dividend Yield (Trailing)
1.81%
Dividend Yield (Forward)
1.87%
Total Yield
1.81%

Company Profile

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
7,604

Competitors

Valuation

Metric
CHGCF
4502
4568
Price/Earnings (Normalized)
22.6015.5448.10
Price/Book Value
4.510.886.16
Price/Sales
6.831.526.50
Price/Cash Flow
21.287.4339.74
Price/Earnings
CHGCF
4502
4568

Financial Strength

Metric
CHGCF
4502
4568
Quick Ratio
4.210.462.74
Current Ratio
5.531.063.49
Interest Coverage
1.9311.76
Quick Ratio
CHGCF
4502
4568

Profitability

Metric
CHGCF
4502
4568
Return on Assets (Normalized)
17.64%2.86%7.33%
Return on Equity (Normalized)
21.05%6.13%13.01%
Return on Invested Capital (Normalized)
20.98%4.78%11.32%
Return on Assets
CHGCF
4502
4568
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoRrrhkpwbfBmnvv$763.3 Bil
JNJ
Johnson & JohnsonJprgqxnzGrwtz$372.2 Bil
MRK
Merck & Co IncVxkvsgpvnHkx$331.2 Bil
ABBV
AbbVie IncGgbmnhpqjZztpv$287.7 Bil
AZN
AstraZeneca PLC ADRRktgwlvdZtvx$243.6 Bil
RHHBY
Roche Holding AG ADRQsfztcxxhWbxjx$211.1 Bil
NVS
Novartis AG ADRLsdvtlmLzhz$209.6 Bil
AMGN
Amgen IncFlrrwskngLjwn$168.9 Bil
PFE
Pfizer IncYghfpjlTkgp$161.8 Bil
SNY
Sanofi SA ADRSfpntystJfqzy$121.2 Bil

Sponsor Center